NEUP
Neuphoria Therapeutics Inc.
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$3.77
+0.27%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- +51.5%
- Free cash flow
- +9025.0%
- Operating cash flow
- +9025.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +49.7%
Three-year CAGR
- Revenue
- +244.4%
- EBITDA
- +99.5%
- EBIT
- +95.8%
- Net income
- +97.6%
- EPS
- —
- Free cash flow
- +626.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026